BioTech 365

MARCH 1, 2021

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development Jon Kratochvil joins as Vice President for Business Development & Licensing for North America … Continue reading →

Business Development 52

Business Development Genome Genomics Development 52

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Business Development Genome Genomics 52

The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 58

Gene Editing Genome Genomics Engineer 58

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Photo courtesy of Bayer.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

The Pharma Data

NOVEMBER 3, 2020

It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

NOVEMBER 5, 2020

VectivBio AG – Based in Switzerland, VectivBio named Sarah Holland as chief business officer and Aditya Venugopal as head of business development. Most recently, Holland served as Global Head of licensing at Lonza AG. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D.

Genome 40

Genome Genomics Medicine Life Science 40